| Status | Study |
| Not yet recruiting |
Study Name: Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy Condition: Invasive Pneumococcal Infection Date: 2017-02-27 Interventions: Biological: PCV13 Other Name: |
| Recruiting |
Study Name: Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Condition: Cryoglobulinemic Vasculitis (CV) Drug-induced Vasculitis E Date: 2016-12-20 |
| Recruiting |
Study Name: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Condition: ANCA-Associated Vasculitis Date: 2016-12-11 Interventions: Drug: CCX168 Orally administer |
| Recruiting |
Study Name: Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Condition: Asthma Date: 2016-12-11 Interventions: Drug: Benralizumab one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every |
| Recruiting |
Study Name: VCRC Tissue Repository Condition: Aortitis Cutaneous Vasculitis Eosinophilic Granulomatosis Date: 2016-11-11 |
| Recruiting |
Study Name: MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS Condition: ANCA-associated Vasculitis Date: 2016-11-02 Interventions: Other: Non interventional study This is a non interventional study because all levies are performed duri |
| Not yet recruiting |
Study Name: Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Condition: Asthma Date: 2016-10-17 Interventions: Drug: Reslizumab All subjects will receive Reslizumab |
| Recruiting |
Study Name: Eosinophilic Granulomatosis With Polyangiitis Cohort Condition: Churg-Strauss Syndrome Date: 2016-09-26 |
| Recruiting |
Study Name: Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD) Condition: Pulmonary Healthy Controls Interstitial Lung Disease Idiop Date: 2016-06-30 Interventions: Device: multiple breath washout tests Devi |
| Recruiting |
Study Name: Rituximab in Eosinophilic Granulomatosis With Polyangiitis Condition: Eosinophilic Granulomatosis With Polyangiitis (EGPA) Date: 2016-05-20 Interventions: Drug: Rituximab 1 g intravenou |